Patients living with one of Australia’s most common forms of leukaemia are set to benefit from expanded access to a breakthrough medicine through the Pharmaceutical Benefits Scheme. From 1 December, access to Venclexta® will be extended in combination with obinutuzumab for the first-line treatment of patients with chronic lymphocytic leukaemia who have co-existing conditions and…
Melanoma of the skin is the fourth most commonly diagnosed cancer in Australia with about 15,691 people diagnosed each year. Sadly, of those who are diagnosed about 1,769 will die each year despite Melanoma being largely a preventable cancer. Federal Leichhardt MP Warren Entsch today visited FNQH Cairns Medical and Skin Cancer Centre to highlight…
Australians living with non-small cell lung cancer and early stage acute lymphoblastic leukaemia will soon be able to access better treatment, thanks to two significant amendments to the Pharmaceutical Benefits Scheme. From December 1, more than 2,200 patients with metastatic non-small cell lung cancer will be able to access Keytruda® (pembrolizumab) as a first line…
Cheaper medicine is on the way for more than 500,000 patients from today with price reductions for common scripts and new medicines added to the Pharmaceutical Benefits Scheme. Medicines to treat lung cancer, lymphoblastic and acute leukaemia and nausea associated with chemotherapy will now be available to patients on the PBS from today for just…